Corneal Cross-Linking
(CXL)

Corneal Cross-Linking (CXL) is an advanced treatment designed to strengthen the cornea and slow or halt the progression of keratoconus and other corneal ectatic disorders. The procedure works by using ultraviolet (UV) light and riboflavin (vitamin B2) eye drops to enhance the cross-linking of collagen fibers within the cornea, improving its stability and structure. CXL is currently the only proven treatment that can stop the worsening of keratoconus and help prevent the need for corneal transplantation in many patients.

Corneal Cross-Linking offers several benefits for patients with progressive keratoconus. The procedure can slow or halt disease progression, preserve vision, strengthen the cornea, and reduce the likelihood of needing a corneal transplant. Because it is minimally invasive, CXL is performed on an outpatient basis and can often be combined with other treatments such as specialty contact lenses, intracorneal ring segments (ICRS), or refractive procedures when appropriate.

While CXL is highly effective, there are some limitations. Patients may experience temporary blurry vision, light sensitivity, irritation, and discomfort during the healing process. Vision stabilization can take several months, and the procedure is not intended to correct refractive errors like LASIK. Patients with advanced corneal thinning may not qualify for treatment, and some individuals may still require glasses or contact lenses after the cornea has stabilized.

The procedure begins with numbing eye drops to ensure patient comfort. Depending on the treatment approach, the outer layer of the cornea may be removed to allow better absorption of riboflavin drops. Riboflavin (vitamin B2) is then applied for approximately 30 minutes before controlled ultraviolet (UV-A) light is used to activate the strengthening process.

Following treatment, a protective bandage contact lens is placed on the eye to support healing. The entire procedure typically takes about one hour per eye, and patients return home the same day.

Patients are prescribed antibiotic and anti-inflammatory eye drops following treatment to support healing and prevent infection. Mild discomfort, light sensitivity, tearing, and irritation are common during the first few days of recovery.

Regular follow-up appointments are necessary to monitor healing and corneal stability. Most patients are advised to avoid rubbing their eyes, swimming, and prolonged exposure to bright light while healing. Vision often stabilizes gradually over a period of three to six months.

Corneal Cross-Linking has a success rate exceeding 90% for stopping the progression of keratoconus. Most patients experience long-term corneal stability, helping preserve vision and reduce the likelihood of future corneal transplantation.

Some patients may also experience modest improvements in corneal shape and visual clarity. Once the cornea has stabilized, many patients find they are better candidates for specialty contact lenses and other vision correction options.